[IFN-tau, a new interferon type I with antiretroviral activity].
Type I interferon (IFN) such as IFN-alpha have demonstrated relative efficiency in HIV-infected patients with Kaposi's sarcoma. Nevertheless, their clinical uses have been restricted by several major side effects. IFN-tau is a non-cytotoxic type I IFN. In the present manuscript, we described its in vitro effects towards HIV replication and its mode of action. IFN-tau is a potent antiviral molecule that interferes with an early step of HIV biological cycle. Moreover, it induces IL-6 synthesis by macrophages, and this cytokine favorises its antiviral efficacy, probably by amplifying the induction of 2', 5'OAS and RNase L. Altogether, these results confirm the interest of IFN-tau as adjuvant therapy in HIV infection, and more particularly in HIV/HCV-infected patients.
Clayette
P
P
CEA, Service de Neurovirologie, DSV/DRM, CRSSA, IPSC, 60-68, Fontenay-Aux-Roses, France.
Martin
M
M
Dereuddre-Bosquet
N
N
Tournay
V
V
Gras
G
G
Martal
J
J
Dormont
D
D
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D015850:Interleukin-6 / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000821:virology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D011257:Pregnancy Proteins / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D012190:Retroviridae / Q000187:drug effects / Q000502:physiology; D012756:Sheep; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D007370:Interferon Type I; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011257:Pregnancy Proteins; D011994:Recombinant Proteins; C020947:interferon tau
Un nouvel interféron de type I doté d'une activité antirétrovirale, L'IFN-tau.